Treatment of Hematological Malignancies With Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation and High Dose, Post-Transplantation Cyclophosphamide
Treatment of Hematological Malignancies
AT Munchel, YL Kasamon, EJ Fuchs
Yes
20110801
2011 Sept 1
Best Pract Res Clin Haematol
Treatment of Hematological Malignancies With Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation and High Dose, Post-Transplantation Cyclophosphamide
Best Pract Res Clin Haematol. 2011 Sept 1;24(3):323-484, AT Munchel, YL Kasamon, EJ Fuchs
Abstract
Abstract
Hematopoietic stem cell transplantation provides the only potential curative option in many patients with hematological malignancies. Finding a suitably matched donor in a timely manner is often difficult. However, most patients have a partially HLA-mismatched (HLA-haploidentical) first-degree relative readily available. Historically, HLA-haploidentical bone marrow transplantation (BMT) has been considered extremely high risk due to high rates of life-threatening graft-versus-host disease (GVHD)...
